急性肝功能衰竭的人工肝治疗现状及进展

doi:10.3969/j.issn.1004-583X.2024.10.012

摘要/Abstract

摘要：

急性肝衰竭(acute liver failure,ALF)发病率不高,但病因复杂,病死率极高。经过传统内科手段治疗的ALF患者存活率低,而肝移植可以显著提高此类患者的生存率,但受限于经济情况、患者自身条件、肝源等因素,许多患者无法接受肝移植治疗。因此人工肝成为临床治疗此类患者的重要手段。世界范围内关于慢加急性肝衰竭以及慢性肝衰竭的研究已很多,但针对急性肝衰竭的研究仍较不成熟。本文描述了各种人工肝模式应用于ALF患者的研究现状及进展,旨在为临床提供依据。

中图分类号:

R575.3

石畅, 李兰娟. 急性肝功能衰竭的人工肝治疗现状及进展[J]. 临床荟萃, 2024, 39(10): 935-939.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.10.012

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I10/935

参考文献 32

[1]	Shingina A, Mukhtar N, Wakim-Fleming J, et al. Acute liver failure guidelines[J]. Am J Gastroenterol, 2023, 118(7): 1128-1153. doi: 10.14309/ajg.0000000000002340 pmid: 37377263
[2]	Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure[J]. Curr Opin Crit Care, 2019, 25(2): 187-191. doi: 10.1097/MCC.0000000000000584 pmid: 30672818
[3]	Khamri W, Abeles RD, Hou TZ, et al. Increased expression of cytotoxic T-lymphocyte-Associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure[J]. Gastroenterology, 2017, 153(1): 263-276.e8. doi: S0016-5085(17)30332-3 pmid: 28363639
[4]	白浪, 陈煜, 陈源文, 等. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38(4):767-775.
[5]	Wendon J, Cordoba J, Dhawan A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66(5): 1047-1081. doi: S0168-8278(16)30708-5 pmid: 28417882
[6]	Akdogan M, Camci C, Gurakar A, et al. The effect of total plasma exchange on fulminant hepatic failure[J]. J Clin Apher, 2006, 21(2):96-99. pmid: 16142721
[7]	Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. doi: 10.1016/j.jhep.2015.08.018 pmid: 26325537
[8]	Chen KJ, Chen TH, Sue YM, et al. High-volume plasma exchange in a patient with acute liver failure due to non-exertional heat stroke in a sauna[J]. J Clin Apher, 2014, 29(5): 281-283.
[9]	Nakae H, Yonekawa C, Wada H, et al. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure[J]. Ther Apher, 2002, 5(6): 471-475.
[10]	Morgan SM, Zantek ND. Therapeutic plasma exchange for fulminant hepatic failure secondary to Wilson's disease[J]. J Clin Apher, 2012, 27(5): 282-286. doi: 10.1002/jca.21239 pmid: 22718095
[11]	Cheng YL, Chang CH, Chen WT, et al. Prognostic factors and treatment effect of standard-volume plasma exchange for acute and acute-on-chronic liver failure: A single-center retrospective study[J]. Transfus Apher Sci, 2018, 57(4): 537-543.
[12]	Liu CT, Chen TH, Cheng CY. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange[J]. J Clin Apher, 2013, 28(6): 430-434.
[13]	Maiwall R, Bajpai M, Singh A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2022, 20(4): e831-e854.
[14]	Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34(4): 392-398. doi: 10.1002/jca.21690 pmid: 30758886
[15]	Sen S, Ytrebø LM, Rose C, et al. Albumin dialysis: A new therapeutic strategy for intoxication from protein-bound drugs[J]. Intensive Care Med, 2004, 30(3): 496-501.
[16]	Saliba F, Camus C, Durand F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial[J]. Ann Intern Med, 2013, 159(8):522-531. doi: 10.7326/0003-4819-159-8-201310150-00005 pmid: 24126646
[17]	Cardoso FS, Gottfried M, Tujios S, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure[J]. Hepatology, 2018, 67(2): 711-720. doi: 10.1002/hep.29488 pmid: 28859230
[18]	Schmidt LE, Wang LP, Hansen BA. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial[J]. Liver Transpl, 2003, 9(3): 290-297.
[19]	Schmidt LE, Tofteng F, Strauss GI, et al. Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy[J]. Scand J Gastroenterol, 2004, 39(10): 974-980.
[20]	Saliba F, Bañares R, Larsen FS, et al. Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts[J]. Intensive Care Med, 2022, 48(10):1352-1367. doi: 10.1007/s00134-022-06802-1 pmid: 36066598
[21]	Mitzner SR, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system[J]. Ther Apher, 2001, 5(5): 417-422. doi: 10.1046/j.1526-0968.2001.00388.x pmid: 11778928
[22]	Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support[J]. Artif Organs, 1999, 23(4):319-330. doi: 10.1046/j.1525-1594.1999.06122.x pmid: 10226696
[23]	Camus C, Locher C, Saliba F, et al. Outcome of patients treated with molecular adsorbent recirculating system albumin dialysis: A national multicenter study[J]. JGH Open, 2020, 4(4): 757-763. doi: 10.1002/jgh3.12359 pmid: 32782967
[24]	Kanjo A, Ocskay K, Gede N, et al. Efficacy and safety of liver support devices in acute and hyperacute liver failure: A systematic review and network meta-analysis[J]. Sci Rep, 2021, 11(1): 4189. doi: 10.1038/s41598-021-83292-z pmid: 33602961
[25]	Fujiwara K, Abe R, Yasui S, et al. High recovery rate of consciousness by high-volume filtrate hemodiafiltration for fulminant hepatitis[J]. Hepatol Res, 2018, 49(2): 224-231.
[26]	Fujiwara K, Oda S, Abe R, et al. On-line hemodiafiltration or high-flow continuous hemodiafiltration is one of the most effective artificial liver support devices for acute liver failure in Japan[J]. J Hepatobiliary Pancreat Sci, 2015, 22(3): 246-247. doi: 10.1002/jhbp.204 pmid: 25565563
[27]	Takikawa Y, Kakisaka K, Suzuki Y, et al. Multicenter study on the consciousness-regaining effect of a newly developed artificial liver support system in acute liver failure: An on-line continuous hemodiafiltration system[J]. Hepatol Res, 2020, 51(2):216-226.
[28]	Nakae H, Eguchi Y, Saotome T, et al. Multicenter study of plasma diafiltration in patients with acute liver failure[J]. Ther Apher Dial, 2010, 14(5):444-450.
[29]	Pless G, Sauer IM. Bioartificial liver: current status[J]. Transplant Proc, 2005, 37(9): 3893-3895.
[30]	朱雪晶, 黄伟健, 鄢和新. 生物型人工肝支持系统种子细胞的来源与应用[J]. 临床肝胆病杂志, 2024, 40(2):246-251.
[31]	Shi XL, Gao Y, Yan Y, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes[J]. Cell Res, 2016, 26(2): 206-216.
[32]	Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30(5): 617-631.e8. doi: 10.1016/j.stem.2023.03.013 pmid: 37059100

急性肝功能衰竭的人工肝治疗现状及进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘海燕，钱晶，潘闽，于小红. 伊伐布雷定对急性失代偿性左心室射血分数降低型心力衰竭患者的近期疗效[J]. 临床荟萃, 2020, 35(4): 317-321.
[2]	梁玉玲, 李文晞, 古学文. 天麻钩藤饮联合厄贝沙坦治疗原发性高血压的随机对照临床试验[J]. 临床荟萃, 2020, 35(12): 1097-1100.
[3]	施伯瀚, 黄春萌, 朱燕, 陈柱, 厉坤鹏, 罗云, 肖忠新, 唐燕甫, 徐倩, 徐燕. 肌内效贴对膝关节骨性关节炎患者步行能力短期临床疗效[J]. 临床荟萃, 2020, 35(12): 1111-1115.
[4]	王娜，朱育刚，刘伟光，王德峰. 糖尿病足抗生素规范化治疗[J]. 临床荟萃, 2019, 34(8): 702-706.
[5]	黄德波，毛献泉，徐振强，冯国宽，许福观，何玉燕. 支架取栓与静脉溶栓治疗急性大动脉闭塞型脑梗死的疗效对比[J]. 临床荟萃, 2019, 34(7): 617-621.
[6]	王敏a, 高微b, 胡小伟a, 吴超b, 徐敏a. 多病灶难治性癫痫的术前定位和手术疗效分析[J]. 临床荟萃, 2018, 33(12): 1031-1035.
[7]	刘欣燕, 魏红艳, 戴献利, 刘颖. 经气管镜微创介入治疗中心型肺癌疗效分析[J]. 临床荟萃, 2016, 31(4): 389-391.
[8]	陈涵1，王娟2，张静2. 紫杉醇脂质体与多西紫杉醇对乳腺癌疗效及安全性临床观察[J]. 临床荟萃, 2016, 31(11): 1206-1208.
[9]	李忱, 王景, 史小虎, 刘晋河, 郝伟欣, 董振华, 张文. 35例难治性SAPHO综合征患者应用肿瘤坏死因子α拮抗剂的治疗随访[J]. 临床荟萃, 2016, 31(1): 45-47.
[10]	王立伟;王子珍. 耐多药肺结核病患者应用化疗方案的疗效分析[J]. 临床荟萃, 2014, 29(6): 605-607.
[11]	王霞;佟飞;陈慧;霍书花;刘芳;刘志宽;张曼莉;赵昆;刘芙蓉. ω-3多不饱和脂肪酸对腹部脓毒症患者的临床疗效[J]. 临床荟萃, 2014, 29(5): 502-504508.
[12]	吴丽阳;胡菊梅. 毒素分型对含莫西沙星的序贯疗法根除幽门螺杆菌疗效的影响[J]. 临床荟萃, 2013, 28(9): 1024-1025.
[13]	索晓慧;王丽;董丽洁;高建军;张健维. 3种途径补铁治疗育龄期妇女缺铁性贫血的疗效观察[J]. 临床荟萃, 2013, 28(9): 1000-1002.
[14]	张雄鹰. Rho激酶抑制剂治疗急性脑梗死的疗效观察[J]. 临床荟萃, 2013, 28(4): 439-440.
[15]	王晓佳. 血管紧张素Ⅱ受体拮抗剂治疗心力衰竭的临床观察[J]. 临床荟萃, 2013, 28(12): 1417-1418.